AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22677537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 M sodium chloride (salty) alone and mixed with barium
Number of subjects: 80
Study 22677537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.032 M caffeine (bitter) alone and mixed with barium
Number of subjects: 80
Study 22677537 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium combined with taste
Number of subjects: 80
Study 22677537 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (older women)
Number of subjects: 80
Study 19388819 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dapivirine from intravaginal ring (IVR)
Number of subjects: 25
Study 19388819 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dapivirine from intravaginal ring (IVR)
Number of subjects: 25
Study 19388819 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dapivirine from IVR
Number of subjects: 25
Study 19388819 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dapivirine from IVR
Number of subjects: 25
Study 19388819 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg and 25 mg dapivirine from IVR
Number of subjects: 25
Study 17465499 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL2/CCR2 mutations
Number of subjects: 284
Study 17465499 — intervention group
Group type: COMPARATOR
Intervention: Non-infected matched controls
Number of subjects: 284
Study 17465499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained response (SR)
Number of subjects: 284
Study 17465499 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sustained response (NSR)
Number of subjects: 284
Study 17465499 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameters influencing fibrosis and treatment response
Number of subjects: 284
Study 15633894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride (10 mg by mouth daily for 1 week)
Number of subjects: 14
Study 15633894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11444086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg daily) + Vitamin C (500 mg)
Number of subjects: 68
Study 11444086 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C only
Number of subjects: 68
Study 9473536 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure at 5 ppm
Number of subjects: 10
Study 9473536 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure at 25 ppm
Number of subjects: 10
Study 9473536 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure at 50 ppm
Number of subjects: 10
Study 9473536 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure (all levels)
Number of subjects: 10
Study 7999527 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 (20 mg/kg over 10 min, followed by 10 mg/kg/h)
Number of subjects: 6
Study 7999527 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 7999527 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 and Saline infusion
Number of subjects: 6
Study 3141642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fybogel (Ispaghula husk), one sachet twice daily
Number of subjects: 68
Study 3141642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 29153919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 100
Study 28777771 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral therapy delivered through the Internet
Number of subjects: 138
Study 25197005 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium (combined therapy)
Number of subjects: 0
Study 25197005 — intervention group
Group type: COMPARATOR
Intervention: Dual bronchodilator therapy (albuterol and ipratropium)
Number of subjects: 0
Study 25197005 — intervention group
Group type: COMPARATOR
Intervention: No treatment (pre-dose values)
Number of subjects: 0
Study 24557960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with amoxicillin and lansoprazole for the first 5 days and clarithromycin, ornidazole and lansoprazole for another 5 days.
Number of subjects: 61
Study 24557960 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy with amoxicillin, clarithromycin, and lansoprazole for 14 days.
Number of subjects: 61
Study 20031690 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush technique
Number of subjects: 424
Study 20031690 — intervention group
Group type: COMPARATOR
Intervention: Culotte technique
Number of subjects: 424
Study 16465666 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home based aerobic exercise program
Number of subjects: 39
Study 16465666 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home based stretching exercise program
Number of subjects: 39
Study 16465666 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 12622343 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnitude reinforcement condition
Number of subjects: 6
Study 12622343 — intervention group
Group type: COMPARATOR
Intervention: Low magnitude reinforcement condition
Number of subjects: 6
Study 11207001 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 45
Study 11207001 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 45
Study 9046727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive precoated (APC) brackets
Number of subjects: 75
Study 9046727 — intervention group
Group type: COMPARATOR
Intervention: Control brackets
Number of subjects: 75
Study 8396534 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of MK-0679
Number of subjects: 8
Study 8396534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3750367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use solution
Number of subjects: 12
Study 3750367 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized form
Number of subjects: 12
Study 3750367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study 29377592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy protein supplementation (20 g d-1)
Number of subjects: 25
Study 29377592 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo
Number of subjects: 25
Study 27317931 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day
Number of subjects: 17515
Study 27317931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17515
Study 25465497 — intervention group
Group type: EXPERIMENTAL
Intervention: FDR-targeted decision aid (general PCa decision aid booklet plus a decision aid DVD targeted specifically for FDRs)
Number of subjects: 78
Study 25465497 — intervention group
Group type: COMPARATOR
Intervention: General decision aid
Number of subjects: 78
Study 22531237 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T vaccine (group 1)
Number of subjects: 2133
Study 22531237 — intervention group
Group type: COMPARATOR
Intervention: Licensed DTwP-Hep B//Hib and oral poliovirus vaccines (group 2)
Number of subjects: 2133
Study 20447541 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated H‐FABP levels (> or =6 ng/ml)
Number of subjects: 126
Study 20447541 — intervention group
Group type: COMPARATOR
Intervention: Low H‐FABP levels (<6 ng/ml)
Number of subjects: 126
Study 20447541 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FABP levels (median 11.2 ng/ml)
Number of subjects: 126
Study 20447541 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FABP combined with tachycardia
Number of subjects: 126
Study 20447541 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FABP levels
Number of subjects: 126
Study 18348469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat vegetarian diet
Number of subjects: 24
Study 18348469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat non-vegetarian diet
Number of subjects: 24
Study 18348469 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 24
Study 18348469 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vegetarian diets
Number of subjects: 24
Study 18348469 — intervention group
Group type: COMPARATOR
Intervention: High-fat non-vegetarian diet
Number of subjects: 24
Study 15833571 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of Change (SOC) or ladder scales of intentions to quit, assessed at 0, 7, 14, and 30 days
Number of subjects: 115
Study 15833571 — intervention group
Group type: COMPARATOR
Intervention: Two-assessment group (0 and 30 days, no intervention)
Number of subjects: 115
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: TIMI grade 2/3 flow
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: Reduced CTFCs (faster flow)
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: Open microvasculature (TMPG 2/3)
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: Rescue percutaneous coronary intervention (PCI) of closed arteries (TFG 0/1) at 90 minutes
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive PCI of open (TFG 2/3) arteries
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: Patency (TFG 2/3)
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: CTFC
Number of subjects: 0
Study 11997276 — intervention group
Group type: COMPARATOR
Intervention: TMPG 2/3
Number of subjects: 0
Study 9521968 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 185
Study 9521968 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 185
Study 8536154 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (including standard health education materials and intensive individual interventions)
Number of subjects: 4316
Study 8536154 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 4316
Study 2367159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gamma-globulin treatment
Number of subjects: 0
Study 2367159 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 758758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol
Number of subjects: 20
Study 758758 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study 30842035 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially Evaluated Cold Pressor Task (SECPT)
Number of subjects: 100
Study 30842035 — intervention group
Group type: COMPARATOR
Intervention: Warm-water control condition
Number of subjects: 100
Study 28730418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg IV low dose cosyntropin test
Number of subjects: 22
Study 28730418 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg IM medium dose cosyntropin test
Number of subjects: 22
Study 28730418 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg IM standard dose cosyntropin test (30 min)
Number of subjects: 22
Study 28730418 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg IM standard dose cosyntropin test (60 min)
Number of subjects: 22
Study 28730418 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test
Number of subjects: 22
Study 26367388 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOE
Number of subjects: 36
Study 26367388 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 23248256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel with sorafenib (CPS)
Number of subjects: 823
Study 23248256 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 823
Study 20629805 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CBM training
Number of subjects: 82
Study 20629805 — intervention group
Group type: COMPARATOR
Intervention: Negative CBM training
Number of subjects: 82
Study 18751690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg twice daily) with rifampicin-based tuberculosis therapy
Number of subjects: 53
Study 18751690 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (200 mg twice daily) without rifampicin-based tuberculosis therapy
Number of subjects: 53
Study 17725475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing during sitting
Number of subjects: 10
Study 17725475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing during right side‐lying
Number of subjects: 10
Study 16126933 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifiers
Number of subjects: 369
Study 16126933 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchanger filters
Number of subjects: 369
Study 12461419 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine/lamivudine/indinavir
Number of subjects: 170
Study 12461419 — intervention group
Group type: COMPARATOR
Intervention: zidovudine/lamivudine/indinavir
Number of subjects: 170
Study 10496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir 450, 875, 1750 and 2625 mg once daily for 3 days
Number of subjects: 39
Study 10496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 39
Study 10496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir 900 mg/day
Number of subjects: 39
Study 8768808 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with 3,700 micrograms histamine/l
Number of subjects: 1
Study 8768808 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with 200 micrograms histamine/l
Number of subjects: 1
Study 8768808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (histamine-poor wine)
Number of subjects: 1
Study 2015149 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 0.1 mg kg‐1
Number of subjects: 310
Study 2015149 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 0.2 mg kg‐1
Number of subjects: 310
Study 2015149 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 0.4 mg kg‐1
Number of subjects: 310
Study 2015149 — intervention group
Group type: COMPARATOR
Intervention: no lignocaine
Number of subjects: 310
Study 6258871 — intervention group
Group type: EXPERIMENTAL
Intervention: APE (adriamycin 35 mg/m2 IV D1 Q 3 weeks; procarbazine 60 mg/m2 PO D1-10 Q 3 weeks; VP16-213 130 mg/m2 IV D8, 15 Q 3 weeks)
Number of subjects: 39
Study 6258871 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCC (methotrexate 15 mg/m2 IV or PO twice weekly D8-21 Q 3 weeks; Oncovin 1.5 mg/m2 IV D8, 15 Q 3 weeks; cyclophosphamide 600 mg/m2 IV D1 Q 3 weeks; CCNU 60 mg/m2 PO Q 6 weeks)
Number of subjects: 39
Study 6258871 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (APE and MOCC)
Number of subjects: 39
Study 6258871 — intervention group
Group type: COMPARATOR
Intervention: Alternate regimen after crossover
Number of subjects: 39
Study 6258871 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 39
Study 31633520 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐fidelity simulator
Number of subjects: 59
Study 31633520 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching model
Number of subjects: 59
Study 27882595 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive hands-on experience
Number of subjects: 0
Study 27882595 — intervention group
Group type: COMPARATOR
Intervention: Storybook
Number of subjects: 0
Study 25930049 — intervention group
Group type: COMPARATOR
Intervention: Primary care-based treatment visit
Number of subjects: 2146
Study 25930049 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care visit
Number of subjects: 2146
Study 24460645 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 35 ± 4 days
Number of subjects: 7581
Study 24460645 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily for 10 ± 4 days then placebo up to day 35
Number of subjects: 7581
Study 24460645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7581
Study 22832965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 15 weeks
Number of subjects: 9
Study 19299767 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt wire‐guided bronchial blocker (BB)
Number of subjects: 104
Study 19299767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen Flexi‐tip bronchial blocker (BB)
Number of subjects: 104
Study 19299767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Uni‐blocker (BB)
Number of subjects: 104
Study 19299767 — intervention group
Group type: COMPARATOR
Intervention: Left‐sided double‐lumen tube (DLT)
Number of subjects: 104
Study 17584267 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD stress and shock management program (six-week format)
Number of subjects: 0
Study 17584267 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD stress and shock management program (one-day workshop format)
Number of subjects: 0
Study 17584267 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16892580 — intervention group
Group type: EXPERIMENTAL
Intervention: Before hemodialysis
Number of subjects: 48
Study 16892580 — intervention group
Group type: EXPERIMENTAL
Intervention: After hemodialysis
Number of subjects: 48
Study 16892580 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 48
Study 16892580 — intervention group
Group type: COMPARATOR
Intervention: Kidney graft recipients
Number of subjects: 48
Study 12145118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance sessions
Number of subjects: 12
Study 12145118 — intervention group
Group type: COMPARATOR
Intervention: Walking sessions
Number of subjects: 12
Study 9690731 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily for 7 days
Number of subjects: 15
Study 9690731 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 250 mg on days 1, 2, 4 and 6
Number of subjects: 15
Study 2622725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sec. rate of digit presentation
Number of subjects: 123
Study 2622725 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐dB sound-pressure level (SPL) of white masking noise at 1-sec. rate
Number of subjects: 123
Study 2622725 — intervention group
Group type: COMPARATOR
Intervention: 70‐dB sound-pressure level (SPL) of white masking noise at 1-sec. rate
Number of subjects: 123
Study 2622725 — intervention group
Group type: COMPARATOR
Intervention: 1 sec. rate of digit presentation
Number of subjects: 123
Study 277678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% sodium fluoride
Number of subjects: 0
Study 277678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strontium and fluoride treatment
Number of subjects: 0
Study 277678 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% strontium chloride
Number of subjects: 0
Study 277678 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium fluoride
Number of subjects: 0
Study 31163551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalin saline local injection (5 ml, concentration 1:200,000)
Number of subjects: 50
Study 31163551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 50
Study 31163551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (post-surgery)
Number of subjects: 50
Study 29442057 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 960
Study 29442057 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (Control)
Number of subjects: 960
Study 25271172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) metronidazole, 15 mg/kg
Number of subjects: 12
Study 25271172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 12
Study 25271172 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 1-2.5 days and 10-12 days of age
Number of subjects: 12
Study 22711058 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote assessment via videoconferencing
Number of subjects: 10
Study 22711058 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 10
Study 21335973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with melissa oil
Number of subjects: 114
Study 21335973 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 114
Study 21335973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 20027852 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration session (frequencies 35-40 Hz) for 30 min before the dive
Number of subjects: 14
Study 20027852 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control dive)
Number of subjects: 14
Study 16952493 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 24
Study 16952493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg 3 times daily)
Number of subjects: 24
Study 16952493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14973303 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg)
Number of subjects: 12
Study 14973303 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (2.5 microg/kg)
Number of subjects: 12
Study 11914029 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH administration
Number of subjects: 0
Study 11914029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 9136788 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient intervention during the surgery clerkship
Number of subjects: 153
Study 8123395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 16
Study 8123395 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 16
Study 3565116 — intervention group
Group type: EXPERIMENTAL
Intervention: Advised in advance of the biological test
Number of subjects: 0
Study 3565116 — intervention group
Group type: EXPERIMENTAL
Intervention: Live explanation and demonstration of the biological testing procedure
Number of subjects: 0
Study 3565116 — intervention group
Group type: COMPARATOR
Intervention: Advised of the testing procedure only after completing their questionnaire
Number of subjects: 0
Study 28917618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap Balancing (GB)
Number of subjects: 103